ZA200208162B - Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations. - Google Patents
Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations. Download PDFInfo
- Publication number
- ZA200208162B ZA200208162B ZA200208162A ZA200208162A ZA200208162B ZA 200208162 B ZA200208162 B ZA 200208162B ZA 200208162 A ZA200208162 A ZA 200208162A ZA 200208162 A ZA200208162 A ZA 200208162A ZA 200208162 B ZA200208162 B ZA 200208162B
- Authority
- ZA
- South Africa
- Prior art keywords
- cilobradine
- treatment
- hypertrophy
- bradycardiac
- myocardial diseases
- Prior art date
Links
- 206010020880 Hypertrophy Diseases 0.000 title claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 title claims description 6
- 230000000059 bradycardiac effect Effects 0.000 title description 12
- 239000000126 substance Substances 0.000 title description 12
- 239000003814 drug Substances 0.000 title 1
- OBUFMJDDZTXJPY-NRFANRHFSA-N 3-[[(3s)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN1C[C@@H](CN2C(CC3=CC(OC)=C(OC)C=C3CC2)=O)CCC1 OBUFMJDDZTXJPY-NRFANRHFSA-N 0.000 claims description 24
- 229950010208 cilobradine Drugs 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 9
- KEDQCFRVSHYKLR-UHFFFAOYSA-N 3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCN1C(=O)CC2=CC(OC)=C(OC)C=C2CC1 KEDQCFRVSHYKLR-UHFFFAOYSA-N 0.000 claims description 8
- 229950003419 zatebradine Drugs 0.000 claims description 8
- OXTYVEUAQHPPMV-UHFFFAOYSA-N Alinidine Chemical compound ClC1=CC=CC(Cl)=C1N(CC=C)C1=NCCN1 OXTYVEUAQHPPMV-UHFFFAOYSA-N 0.000 claims description 7
- 229950010767 alinidine Drugs 0.000 claims description 7
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 6
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 3
- 229960005187 telmisartan Drugs 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 235000019759 Maize starch Nutrition 0.000 description 9
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- -1 carvedolol Chemical compound 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940116364 hard fat Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- RXKTVGMZJMDNLF-UHFFFAOYSA-N 7,8-dimethoxy-1,2,3,5-tetrahydro-3-benzazepin-4-one Chemical compound C1CNC(=O)CC2=C1C=C(OC)C(OC)=C2 RXKTVGMZJMDNLF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10018401A DE10018401A1 (de) | 2000-04-13 | 2000-04-13 | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200208162B true ZA200208162B (en) | 2003-10-17 |
Family
ID=7638652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200208162A ZA200208162B (en) | 2000-04-13 | 2002-10-10 | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7208508B2 (ru) |
| EP (2) | EP1276476B1 (ru) |
| JP (1) | JP3905386B2 (ru) |
| KR (1) | KR20020089453A (ru) |
| CN (1) | CN1245963C (ru) |
| AT (1) | ATE330588T1 (ru) |
| AU (2) | AU7048401A (ru) |
| BG (1) | BG65816B1 (ru) |
| BR (1) | BR0109996A (ru) |
| CA (2) | CA2575059A1 (ru) |
| CY (1) | CY1105081T1 (ru) |
| CZ (1) | CZ300549B6 (ru) |
| DE (2) | DE10018401A1 (ru) |
| DK (1) | DK1276476T3 (ru) |
| EA (1) | EA006977B1 (ru) |
| EE (1) | EE05099B1 (ru) |
| ES (1) | ES2266216T3 (ru) |
| HR (1) | HRP20020815A2 (ru) |
| HU (1) | HU228387B1 (ru) |
| IL (2) | IL152103A0 (ru) |
| ME (1) | MEP45908A (ru) |
| MX (1) | MXPA02009935A (ru) |
| NO (1) | NO330311B1 (ru) |
| NZ (1) | NZ521934A (ru) |
| PL (1) | PL215235B1 (ru) |
| PT (1) | PT1276476E (ru) |
| RS (1) | RS51478B (ru) |
| SI (1) | SI1276476T1 (ru) |
| SK (1) | SK286075B6 (ru) |
| TR (1) | TR200202326T2 (ru) |
| UA (1) | UA78679C2 (ru) |
| WO (1) | WO2001078699A2 (ru) |
| ZA (1) | ZA200208162B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| SI1362590T1 (en) * | 2002-07-25 | 2004-04-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| EP3045174A1 (en) * | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| ES2404939T3 (es) * | 2005-06-27 | 2013-05-29 | Daiichi Sankyo Company, Limited | Preparación farmacéutica que contiene un antagonista del receptor de la angiotensina II y un bloqueador de los canales de calcio |
| US20090247572A1 (en) * | 2005-08-23 | 2009-10-01 | Koichi Wada | Agent for treating atrial fibrillation |
| EP1762179A1 (en) | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
| FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| EP1908469A1 (en) * | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| MX346039B (es) | 2009-05-20 | 2017-03-03 | Boehringer Ingelheim Vetmedica Gmbh | Solucion farmaceutica bebible de telmisartan. |
| FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| KR101296743B1 (ko) * | 2011-02-17 | 2013-08-20 | 한국과학기술연구원 | 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법 |
| BR112014003117A2 (pt) | 2011-08-12 | 2017-06-13 | Boehringer Ingelheim Vetmedica Gmbh | inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino |
| EP2953612A1 (en) | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit-of-parts |
| CA3067918A1 (en) | 2017-07-07 | 2019-01-10 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats |
| KR102398532B1 (ko) | 2020-07-20 | 2022-05-13 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 조성물 |
| KR102331806B1 (ko) | 2020-07-20 | 2021-12-01 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 바이오 마커 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759125A (fr) | 1969-11-19 | 1971-05-18 | Boehringer Sohn Ingelheim | Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer |
| DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| US5175157A (en) * | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| DE3541811A1 (de) * | 1985-11-27 | 1987-06-04 | Thomae Gmbh Dr K | Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE3736866A1 (de) * | 1987-10-30 | 1989-05-11 | Thomae Gmbh Dr K | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz |
| DE3805635A1 (de) | 1988-02-24 | 1989-09-07 | Thomae Gmbh Dr K | Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| RU2078536C1 (ru) * | 1993-09-02 | 1997-05-10 | Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско | Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией |
| PL313621A1 (en) * | 1993-09-24 | 1996-07-08 | Procter & Gamble | Novel 14-aminosteroid compounds containing desoxy oxygen-substituted sugar |
| US5595987A (en) * | 1994-07-22 | 1997-01-21 | The Trustees Of Columbia University In The City Of New York | Method of slowing ventricular arrhythmias using zatebradine |
| US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
| DE19741635A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| ID27664A (id) | 1998-07-10 | 2001-04-19 | Novartis Ag | Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| CA2435526A1 (en) | 2002-07-25 | 2004-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| EP1762179A1 (en) * | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
-
2000
- 2000-04-13 DE DE10018401A patent/DE10018401A1/de not_active Withdrawn
-
2001
- 2001-04-07 DK DK01949281T patent/DK1276476T3/da active
- 2001-04-07 EA EA200201053A patent/EA006977B1/ru not_active IP Right Cessation
- 2001-04-07 IL IL15210301A patent/IL152103A0/xx unknown
- 2001-04-07 BR BR0109996-5A patent/BR0109996A/pt active Pending
- 2001-04-07 KR KR1020027013688A patent/KR20020089453A/ko not_active Application Discontinuation
- 2001-04-07 US US10/257,481 patent/US7208508B2/en not_active Expired - Fee Related
- 2001-04-07 TR TR2002/02326T patent/TR200202326T2/xx unknown
- 2001-04-07 WO PCT/EP2001/004034 patent/WO2001078699A2/de active IP Right Grant
- 2001-04-07 MX MXPA02009935A patent/MXPA02009935A/es active IP Right Grant
- 2001-04-07 SK SK1458-2002A patent/SK286075B6/sk not_active IP Right Cessation
- 2001-04-07 RS YUP-769/02A patent/RS51478B/sr unknown
- 2001-04-07 CA CA002575059A patent/CA2575059A1/en not_active Abandoned
- 2001-04-07 AU AU7048401A patent/AU7048401A/xx active Pending
- 2001-04-07 ME MEP-459/08A patent/MEP45908A/xx unknown
- 2001-04-07 HU HU0300917A patent/HU228387B1/hu not_active IP Right Cessation
- 2001-04-07 EP EP01949281A patent/EP1276476B1/de not_active Expired - Lifetime
- 2001-04-07 PL PL357827A patent/PL215235B1/pl unknown
- 2001-04-07 ES ES01949281T patent/ES2266216T3/es not_active Expired - Lifetime
- 2001-04-07 AU AU2001270484A patent/AU2001270484B2/en not_active Ceased
- 2001-04-07 CN CNB018079598A patent/CN1245963C/zh not_active Expired - Fee Related
- 2001-04-07 EP EP06111485A patent/EP1666042A3/de not_active Withdrawn
- 2001-04-07 CZ CZ20023752A patent/CZ300549B6/cs not_active IP Right Cessation
- 2001-04-07 CA CA002404120A patent/CA2404120C/en not_active Expired - Fee Related
- 2001-04-07 DE DE50110262T patent/DE50110262D1/de not_active Expired - Lifetime
- 2001-04-07 AT AT01949281T patent/ATE330588T1/de active
- 2001-04-07 NZ NZ521934A patent/NZ521934A/en not_active IP Right Cessation
- 2001-04-07 JP JP2001576000A patent/JP3905386B2/ja not_active Expired - Fee Related
- 2001-04-07 PT PT01949281T patent/PT1276476E/pt unknown
- 2001-04-07 EE EEP200200590A patent/EE05099B1/xx not_active IP Right Cessation
- 2001-04-07 SI SI200130616T patent/SI1276476T1/sl unknown
- 2001-07-04 UA UA2002118949A patent/UA78679C2/uk unknown
-
2002
- 2002-09-13 BG BG107103A patent/BG65816B1/bg active Active
- 2002-10-03 IL IL152103A patent/IL152103A/en not_active IP Right Cessation
- 2002-10-10 ZA ZA200208162A patent/ZA200208162B/en unknown
- 2002-10-11 HR HRP20020815 patent/HRP20020815A2/hr not_active Application Discontinuation
- 2002-10-11 NO NO20024924A patent/NO330311B1/no not_active IP Right Cessation
-
2006
- 2006-07-07 CY CY20061100956T patent/CY1105081T1/el unknown
-
2007
- 2007-03-12 US US11/684,974 patent/US20070155679A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070155679A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
| TWI404534B (zh) | 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）且具有經改良穩定性之固體藥學組成物 | |
| JP2020172531A (ja) | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン | |
| CN102724962B (zh) | 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 | |
| JP2011246478A (ja) | テルカゲパントカリウムの固形投与製剤 | |
| CN101351210A (zh) | 11－哌嗪－1－基二苯并[b,f][l,4]硫氮杂卓或其药学上可接受的盐的新用途及其用于口服药物组合物的新用途 | |
| CN101190890B (zh) | 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺 | |
| CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
| EA003584B1 (ru) | Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства | |
| WO2008061968A1 (en) | Benzimidazolone derivates in the treatment of pulmonary arterial hypertension | |
| CN100503606C (zh) | 噻二唑取代的咪唑类抗厌氧菌化合物 | |
| CN102266332B (zh) | 一种含有苯磺酸左旋氨氯地平和替米沙坦的药用组合物及其制备方法 | |
| TWI484955B (zh) | 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物 | |
| CN104644643A (zh) | 一种复方氢氯噻嗪晶体化合物缬沙坦药物组合物 |